Lantern Pharma Inc (LTRN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2024 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -20,781 | -14,906 | -10,400 | -5,441 | -15,962 |
| Depreciation Amortization | -221 | -167 | -85 | -30 | -159 |
| Other Working Capital | 2,228 | 915 | 1,829 | 2,131 | 538 |
| Other Operating Activity | 961 | 317 | 397 | 272 | 1,235 |
| Operating Cash Flow | $-17,813 | $-13,841 | $-8,259 | $-3,069 | $-14,347 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 3,382 | -68 | -752 | -554 | -912 |
| PPE Investments | -13 | -10 | -7 | -2 | -19 |
| Investing Cash Flow | $3,369 | $-78 | $-758 | $-556 | $-930 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 67 | 67 | 55 | 55 | N/A |
| Common Stock Repurchased | N/A | N/A | N/A | N/A | -500 |
| Financing Cash Flow | $67 | $67 | $55 | $55 | $-500 |
| Exchange Rate Effect | -50 | 18 | 2 | -10 | -29 |
| Beginning Cash Position | 21,938 | 21,938 | 21,938 | 21,938 | 37,743 |
| End Cash Position | 7,511 | 8,103 | 12,977 | 18,358 | 21,938 |
| Net Cash Flow | $-14,427 | $-13,835 | $-8,961 | $-3,580 | $-15,805 |
| Free Cash Flow | |||||
| Operating Cash Flow | -17,813 | -13,841 | -8,259 | -3,069 | -14,347 |
| Capital Expenditure | -13 | -10 | -7 | -2 | -19 |
| Free Cash Flow | -17,826 | -13,851 | -8,266 | -3,071 | -14,365 |